Prelude Capital Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Prelude Capital Management’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,097	Closed	-$10K	–	2226
2018 Q2	$10K	Buy	+1,097	New	+$9.87K	﹤0.01%	1494
2016 Q4	–	Sell	-200	Closed	-$1K	–	1935
2016 Q3	$1K	Sell	200 -1,500	-88%	-$9.92K	﹤0.01%	1554
2016 Q2	$12K	Sell	1,700 -500	-23%	-$3.52K	﹤0.01%	1376
2016 Q1	$15K	Buy	2,200 +1,800	+450%	+$13.2K	﹤0.01%	1141
2015 Q4	$4K	Buy	+400	New	+$4.64K	﹤0.01%	1352
2015 Q3	–	Sell	-300	Closed	-$3K	–	1961
2015 Q2	$3K	Buy	300 +2	+0.7%	+$15	﹤0.01%	1640
2015 Q1	$2K	Buy	+298	New	+$1.84K	﹤0.01%	1896

Prelude Capital Management's JNP Position: Q3 2018 in Review

Prelude Capital Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 1,097 shares — an estimated $10K sold.

Prelude Capital Management first reported a position in JNP in Q1 2015 and held it in 7 quarters. The position peaked at $15K in Q1 2016. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.

Prelude Capital Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Prelude Capital Management sold 1,097 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $10K.
Prelude Capital Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 7 quarters.
Prelude Capital Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $15K in Q1 2016.
0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Prelude Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.